Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Baloxavir Marboxil	730
Overall Study	STARTED	Placebo	729
Overall Study	STARTED	Oseltamivir	725
Overall Study	Received Study Drug	Baloxavir Marboxil	728
Overall Study	Received Study Drug	Placebo	728
Overall Study	Received Study Drug	Oseltamivir	722
Overall Study	Intention to Treat Infected Population	Baloxavir Marboxil	388
Overall Study	Intention to Treat Infected Population	Placebo	386
Overall Study	Intention to Treat Infected Population	Oseltamivir	389
Overall Study	COMPLETED	Baloxavir Marboxil	697
Overall Study	COMPLETED	Placebo	695
Overall Study	COMPLETED	Oseltamivir	683
Overall Study	NOT COMPLETED	Baloxavir Marboxil	33
Overall Study	NOT COMPLETED	Placebo	34
Overall Study	NOT COMPLETED	Oseltamivir	42

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02949011/flow